Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
15
Today In Oncology
People With Acromegaly Face Elevated Cancer Risk, Study Finds
Resectable NSCLC Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy
Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers
New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies
MRD-Guided Therapy With Ibrutinib-Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo